EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA

EyePoint, Inc.

DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.
CST reduction of 68.1 microns vs 30.5 microns for control.
82% of DURAVYU 2.7mg eyes were supplement-free vs 50% for control at 16 weeks.
No DURAVYU-related ocular or systemic SAEs reported; no endophthalmitis, vasculitis, or IOI.
Full topline data from VERONA expected in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.